European Medicines Agency recommends next season’s Covid-19 vaccines should target XFG variant
The European Medicines Agency has recommended that next season's Covid-19 vaccines target the XFG variant. This decision aligns with a similar recommendation from the US Food and Drug Administration's advisory panel. The update aims to enhance protection against circulating variants as the virus continues to evolve.
- ▪The EMA recommends updating Covid-19 vaccines for the 2026-27 season to target the XFG variant.
- ▪This recommendation follows a vote by the FDA's advisory panel to target the same variant.
- ▪Vaccines targeting XFG are expected to also provide protection against the BA.3.2 variant.
Opening excerpt (first ~120 words) tap to expand
European Medicines Agency recommends next season’s Covid-19 vaccines should target XFG variantSign up now: Get ST's newsletters delivered to your inboxCovid-19 vaccines still help prevent severe disease and death, but updating shots to better match circulating variants can improve protection as the virus changes.PHOTO: REUTERSPublished May 30, 2026, 10:13 AMUpdated May 30, 2026, 10:13 AMThe European Medicines Agency (EMA) said on May 29 Covid-19 vaccines for the 2026-27 vaccination campaign in Europe should preferably be updated to target the XFG variant.The decision aligns with the US Food and Drug Administration’s (FDA) advisory panel, which on May 28 voted in favour of the same target for next season’s shots.The recommendation, issued by EMA’s Emergency Task Force, is meant to guide…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Straits Times — World.